利用真实世界数据做好研究,来看诸多经典研究实例

2019-03-12 李侗桐 医咖会

近年来,研究者们对真实世界研究的关注度越来越高,希望通过真实世界数据解决临床试验数据无法回答的临床和政策问题。2019年1月30日,《Nature Reviews Clinical Oncology》(影响因子:24.653)发表了一篇题为《Real- world data: towards achieving the achievable in cancer care》的综述,以肿瘤领域为例,详

近年来,研究者们对真实世界研究的关注度越来越高,希望通过真实世界数据解决临床试验数据无法回答的临床和政策问题。2019年1月30日,《Nature Reviews Clinical Oncology》(影响因子:24.653)发表了一篇题为《Real- world data: towards achieving the achievable in cancer care》的综述,以肿瘤领域为例,详细介绍了真实世界数据。我们将这篇综述进行了整理,希望能为你的研究提供一些思路和方向。

本文中提到的真实世界数据(real world data,RWD)是指从癌症注册登记数据库获取的群体水平的数据,而非随机对照试验的数据。FDA将RWD定义为涉及患者疾病诊疗收集的所有相关数据和信息,包括电子健康档案(EHR)、医保、医疗服务流程和诊疗数据信息等。

越来越多研究者利用RWD来进行研究,在PubMed上搜索“real-world data” “real-world evidence”或“registry”,文献数从2002年的2435增加到2016年的14956。作为对照,我们可以看到,结肠癌研究在2002年和2016年的文献数分别为3028次和6420次(图1)。



图1 使用真实世界数据的研究数量在大幅增加

20世纪上半叶,癌症注册登记仅可以简要统计癌症的发病率。至20世纪90年代,研究者在其基础上记录了与癌症有关的治疗和结局信息,为RWD在肿瘤学的早期应用提供了依据。当时美国和加拿大安大略省同时开展研究,建立了治疗信息与初始癌症登记数据之间的联系。

群体水平的癌症登记数据可以从多种渠道获得,比如可以从医院和/或病理记录中获取癌症发病率数据。目前,肿瘤学中使用的RWD主要分为两种来源:现有的病案数据(如美国的SEER–Medicare);设计良好的单一完整数据库(如美国的国家癌症数据库)。

目前已发表的研究中,RWD多来自于癌症注册登记数据库、医院治疗记录和医保等。研究者对多中心EHR、移动终端和可穿戴设备提供的新型RWD也产生了浓厚兴趣。尽管人们对这些新型RWD的内部有效性仍存在质疑,但这些数据确实可以提供更加详尽的患者信息(如吸烟状态、锻炼情况和生物标记物等)。在未来的研究中,应进一步评价这些新型RWD的有效性和适用性。

RWD通常包含3种基本信息:患者、治疗和结局(框1)。每个变量的重要性由所提的研究问题来决定,例如,发病率研究需要的变量(如年龄、性别、诊断日期或肿瘤组织学),要比结局性研究需要的变量少(如疾病程度、治疗意向性、化疗药物和/或剂量)。



在这篇综述中,作者将讨论使用RWD的常见问题以及与RWD质量相关的因素,提供如何使用RWD的框架,RWD的常见研究举例,以及使用RWD进行疗效比较研究时容易犯的错误。

参考文献:

Nat Rev Clin Oncol. 2019 Jan 30. doi: 10.1038/s41571-019-0167-7.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=814560, encodeId=c8da8145600c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Aug 28 08:31:28 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369559, encodeId=4d063695598f, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/13/7468d7f57066754b704e7fbe8b150045.jpg, createdBy=ed065103149, createdName=A_Little_MD, createdTime=Sat Jul 13 01:30:39 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365216, encodeId=e1cc36521694, content=开始学习RWS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a07b1926496, createdName=bioseraph, createdTime=Thu Apr 25 07:00:33 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295220, encodeId=87fc1295220b7, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Mar 14 01:37:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362536, encodeId=c9853625365c, content=努力学习认真的学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Tue Mar 12 21:29:53 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362523, encodeId=b13936252329, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Tue Mar 12 14:49:35 CST 2019, time=2019-03-12, status=1, ipAttribution=)]
    2020-08-28 14818eb4m67暂无昵称

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=814560, encodeId=c8da8145600c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Aug 28 08:31:28 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369559, encodeId=4d063695598f, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/13/7468d7f57066754b704e7fbe8b150045.jpg, createdBy=ed065103149, createdName=A_Little_MD, createdTime=Sat Jul 13 01:30:39 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365216, encodeId=e1cc36521694, content=开始学习RWS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a07b1926496, createdName=bioseraph, createdTime=Thu Apr 25 07:00:33 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295220, encodeId=87fc1295220b7, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Mar 14 01:37:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362536, encodeId=c9853625365c, content=努力学习认真的学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Tue Mar 12 21:29:53 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362523, encodeId=b13936252329, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Tue Mar 12 14:49:35 CST 2019, time=2019-03-12, status=1, ipAttribution=)]
    2019-07-13 A_Little_MD

    。。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=814560, encodeId=c8da8145600c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Aug 28 08:31:28 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369559, encodeId=4d063695598f, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/13/7468d7f57066754b704e7fbe8b150045.jpg, createdBy=ed065103149, createdName=A_Little_MD, createdTime=Sat Jul 13 01:30:39 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365216, encodeId=e1cc36521694, content=开始学习RWS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a07b1926496, createdName=bioseraph, createdTime=Thu Apr 25 07:00:33 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295220, encodeId=87fc1295220b7, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Mar 14 01:37:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362536, encodeId=c9853625365c, content=努力学习认真的学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Tue Mar 12 21:29:53 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362523, encodeId=b13936252329, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Tue Mar 12 14:49:35 CST 2019, time=2019-03-12, status=1, ipAttribution=)]
    2019-04-25 bioseraph

    开始学习RWS

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=814560, encodeId=c8da8145600c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Aug 28 08:31:28 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369559, encodeId=4d063695598f, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/13/7468d7f57066754b704e7fbe8b150045.jpg, createdBy=ed065103149, createdName=A_Little_MD, createdTime=Sat Jul 13 01:30:39 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365216, encodeId=e1cc36521694, content=开始学习RWS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a07b1926496, createdName=bioseraph, createdTime=Thu Apr 25 07:00:33 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295220, encodeId=87fc1295220b7, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Mar 14 01:37:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362536, encodeId=c9853625365c, content=努力学习认真的学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Tue Mar 12 21:29:53 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362523, encodeId=b13936252329, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Tue Mar 12 14:49:35 CST 2019, time=2019-03-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=814560, encodeId=c8da8145600c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Aug 28 08:31:28 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369559, encodeId=4d063695598f, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/13/7468d7f57066754b704e7fbe8b150045.jpg, createdBy=ed065103149, createdName=A_Little_MD, createdTime=Sat Jul 13 01:30:39 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365216, encodeId=e1cc36521694, content=开始学习RWS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a07b1926496, createdName=bioseraph, createdTime=Thu Apr 25 07:00:33 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295220, encodeId=87fc1295220b7, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Mar 14 01:37:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362536, encodeId=c9853625365c, content=努力学习认真的学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Tue Mar 12 21:29:53 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362523, encodeId=b13936252329, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Tue Mar 12 14:49:35 CST 2019, time=2019-03-12, status=1, ipAttribution=)]
    2019-03-12 zwjnj2

    努力学习认真的学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=814560, encodeId=c8da8145600c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Aug 28 08:31:28 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369559, encodeId=4d063695598f, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/13/7468d7f57066754b704e7fbe8b150045.jpg, createdBy=ed065103149, createdName=A_Little_MD, createdTime=Sat Jul 13 01:30:39 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365216, encodeId=e1cc36521694, content=开始学习RWS, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a07b1926496, createdName=bioseraph, createdTime=Thu Apr 25 07:00:33 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295220, encodeId=87fc1295220b7, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Mar 14 01:37:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362536, encodeId=c9853625365c, content=努力学习认真的学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Tue Mar 12 21:29:53 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362523, encodeId=b13936252329, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Tue Mar 12 14:49:35 CST 2019, time=2019-03-12, status=1, ipAttribution=)]
    2019-03-12 SCI我的梦

    谢谢分享

    0

相关资讯

梅斯医学张发宝博士:弥合裂痕——真实世界的临床证据

4月19日,由梅斯医学举办的"2016临床试验论坛"于国家会展中心(上海)召开,此次会议张发宝博士分享了主题为"真实世界的临床证据"的演讲。真实世界研究(RWS)将是未来研究的趋势,相对RCT而言,RWS的研究范围更广,更具有代表性,能够真实地反映研究的情况。 RWS与RCT RWS是起源于实用性的临床试验,属于药物流行病学的范畴。是基于临床真实的情况采取的一种非随

真实世界数据:诺华Entresto®可改善心衰患者生存质量

7月28日,诺华中国宣布心衰药物Entresto® (沙库巴曲缬沙坦钠片,LCZ696)正式获得CFDA批准上市,用于射血分数降低的成人慢性心衰患者,以降低其心血管死亡和心衰住院的风险。11月12日,诺华制药公布了一项来自德国的真实世界研究数据,数据来自射血分数下降的心衰(HFrEF)患者接受了Entresto® (sacubitril/valsartan)治疗。研究数据进一步支持了Entrest

AHA2017:真实世界数据挑战临床试验结果:新型P2Y12抑制剂真的优于氯吡格雷?

P2Y12抑制剂作为急性冠脉综合征(ACS)患者抗血小板治疗的基石药物,关于其药物选择问题一直备受关注。